Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 23;16(24):4422.
doi: 10.3390/nu16244422.

Efficiency of Skeletal Muscle Mass/Weight Measurement for Distinguishing Metabolic Dysfunction-Associated Steatotic Liver Disease: A Prospective Analysis Using InBody Bioimpedance Devices

Miwa Tatsuta  1   2 , Tsutomu Masaki  3 , Shungo Kimura  1 , Yudai Sato  1 , Akemi Tomida  1 , Ichiro Ishikawa  4 , Yu Nakamura  4 , Kei Takuma  2 , Mai Nakahara  2 , Kyoko Oura  2 , Tomoko Tadokoro  2 , Koji Fujita  2 , Joji Tani  2 , Asahiro Morishita  2 , Takashi Himoto  5 , Shinjiro Miyazaki  6 , Tsuyoshi Maeta  7 , Yoshihiro Mori  7 , Fumikazu Kohi  7 , Hideki Kobara  2
Affiliations

Efficiency of Skeletal Muscle Mass/Weight Measurement for Distinguishing Metabolic Dysfunction-Associated Steatotic Liver Disease: A Prospective Analysis Using InBody Bioimpedance Devices

Miwa Tatsuta et al. Nutrients. .

Abstract

Background/objectives: Metabolic dysfunction-associated steatotic liver disease (MASLD) is diagnosed when hepatic steatosis is proven by imaging and one of the five cardiometabolic criteria is present. The relationship between MASLD and body composition components has recently received increased research attention. However, the five cardiometabolic criteria do not include components of body composition. This study aimed to identify significant body composition factors associated with MASLD in patients undergoing health checkups.

Methods: This study included a cohort of 6599 examinees who participated in a health check-up conducted between 2022 and 2023, and their data were prospectively analyzed. The inclusion criteria were undergoing abdominal ultrasonography, alcohol consumption <30 g/day for males or <20 g/day for females, and one of the five cardiometabolic criteria.

Results: Finally, 3864 examinees were enrolled. In total, 1133 (51.8%) males and 454 (27.1%) females had MASLD. Sarcopenia was present in only 0.62% of males and 0.66% of females with MASLD. The MASLD group had significantly lower skeletal muscle mass/weight (SMM/WT) values than the non-MASLD group. Multivariate analysis revealed that SMM/WT was independently associated with MASLD.

Conclusions: SMM/WT was significantly associated with MASLD. Therefore, muscle mass assessment using SMM/WT may be a potential marker for diagnosing MASLD.

Keywords: bioimpedance analysis; body composition components; metabolic dysfunction-associated steatotic liver disease; sarcopenia; skeletal muscle mass.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Diagram illustrating the study flow. We considered 6599 examinees. N, number; HbA1C, glycated hemoglobin; HDL, high-density lipoprotein; MASLD, metabolic dysfunction-associated steatotic liver disease.
Figure 1
Figure 1
Diagram illustrating the study flow. We considered 6599 examinees. N, number; HbA1C, glycated hemoglobin; HDL, high-density lipoprotein; MASLD, metabolic dysfunction-associated steatotic liver disease.
Figure 2
Figure 2
Prevalence of sarcopenia among health checkup examinees. Sarcopenia was identified in 0.62% of males and 0.66% of females with MASLD by the JSH (2nd edition) sarcopenia criteria. SMI, skeletal muscle mass index.
Figure 2
Figure 2
Prevalence of sarcopenia among health checkup examinees. Sarcopenia was identified in 0.62% of males and 0.66% of females with MASLD by the JSH (2nd edition) sarcopenia criteria. SMI, skeletal muscle mass index.
See this image and copyright information in PMC

References

    1. Henry L., Paik J., Younossi Z.M. Review article: The epidemiologic burden of non-alcoholic fatty liver disease across the world. Aliment. Pharmacol. Ther. 2022;56:942–956. doi: 10.1111/apt.17158. - DOI - PubMed
    1. Rinella M.E., Lazarus J.V., Ratziu V., Francque S.M., Sanyal A.J., Kanwal F., Romero D., Abdelmalek M.F., Anstee Q.M., Arab J.P., et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78:1966–1986. doi: 10.1097/HEP.0000000000000520. - DOI - PMC - PubMed
    1. Koda M., Kawakami M., Murawaki Y., Senda M. The impact of visceral fat in nonalcoholic fatty liver disease: Cross-sectional and longitudinal studies. J. Gastroenterol. 2007;42:897–903. doi: 10.1007/s00535-007-2107-z. - DOI - PubMed
    1. Lee Y.H., Jung K.S., Kim S.U., Yoon H.J., Yun Y.J., Lee B.W., Kang E.S., Han K.H., Lee H.C., Cha B.S. Sarcopaenia is associated with NAFLD independently of obesity and insulin resistance: Nationwide surveys (KNHANES 2008–2011) J. Hepatol. 2015;63:486–493. doi: 10.1016/j.jhep.2015.02.051. - DOI - PubMed
    1. Tokushige K., Ikejima K., Ono M., Eguchi Y., Kamada Y., Itoh Y., Akuta N., Yoneda M., Iwasa M., Yoneda M., et al. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020. Hepatol. Res. 2021;51:1013–1025. doi: 10.1111/hepr.13688. - DOI - PubMed

LinkOut - more resources